Startup profile for KymaThera: latest funding, latest known valuation, total disclosed funding, investors, status, sources, and why the company is interesting. Part of the Venture Capital Tracker startup directory.

Startup profile · funding coverage

KymaThera funding, valuation and investors

Precision-medicine biotech developing mutant-selective PI3Kα inhibitors for cancer and vascular malformations.

Verified company research · funding, investors and latest developments

Keep track of KymaThera

Save this profile to your VCT watchlist for a quick return.

View watchlist

Funding, valuation & investors

Answer-first snapshot

Latest funding

Series B

$80 million · October 6, 2026

Latest known valuation

Not publicly disclosed

Total disclosed equity funding

$80M

Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.

Current status

private

series b · San Diego, California, United States

Investors in latest funding

Lead: Alta Partners

Other: Venrock , Foresite Capital , J. Wood Capital

Sources: latest funding · prnewswire.com Last verified: 2026-10-08

Overview

KymaThera is a San Diego biotechnology company developing structure-guided small-molecule precision medicines. Its lead program, K-1728, is an investigational oral pan-mutant selective PI3Kα inhibitor designed to cover kinase- and helical-domain mutations while sparing wild-type PI3Kα.

Why KymaThera is interesting

K-1728 targets a clinically validated pathway where efficacy has been constrained by hyperglycemia and incomplete mutation coverage. The $80 million Series B is intended to carry the wholly owned program into Phase 1 and through initial clinical proof-of-concept.

Product & use cases

K-1728 is an oral PI3Kα inhibitor designed to inhibit disease-driving kinase- and helical-domain mutations while limiting inhibition of the wild-type protein. KymaThera plans development in HR-positive/HER2-negative breast cancer and PI3Kα-driven vascular malformations.

  • HR-positive, HER2-negative PI3Kα-mutant breast cancer.
  • PI3Kα-driven vascular malformations.

Key facts

  • $80 million Series B announced as closed on October 6, 2026.
  • More than $100 million raised since formation.
  • Phase 1 patient dosing targeted for Q4 2026.

Funding history (newest first)

Investors in our directory

Funds linked from KymaThera's profile — open a fund page for stage focus and related deal articles.

Competitive landscape

Edge: A structure-based design platform and a claimed preclinical selectivity window that could broaden mutation coverage while reducing wild-type PI3Kα toxicity. Those benefits remain unproven in patients.

KymaThera enters a validated but competitive PI3Kα field. Its differentiation depends on whether pan-mutant coverage and wild-type sparing translate from preclinical models into human safety, exposure and response data.

  • Novartis / Piqray incumbent

    Approved PI3Kα inhibitor validating the pathway, but limited by tolerability and mutation coverage.

  • Roche / Itovebi incumbent

    Approved mutant-selective PI3Kα therapy that raises the clinical bar in breast cancer.

  • Eli Lilly / STX-478 direct

    Mutant-selective PI3Kα program competing on selectivity, tolerability and breadth.

Industries

Market / IPO context

Editorial / static context — not a live quote.

FAQs about KymaThera

Practical answers founders, operators, and investors typically search for.

KymaThera closed an $80 million Series B led by Alta Partners.
The company says the proceeds will advance K-1728 into Phase 1 and through initial clinical proof-of-concept.

By Venture Capital Tracker

Last updated:

Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.